CDK6 and acute myeloid leukemia: Our data, thus, support a concept where, in addition to the regulatory effect of CDK6 on FLT3 and PIM1 kinases [18], transcriptional control of AKT and AURORA also contributes to the antileukemic activity of palbociclib in mutant FLT3-mediated AML.